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Objectives: To functionalise novel chlorhexidine (CHX) particles with iron oxide (Fe3O4) 
nanoparticles and control their release kinetics in a dental resin using an external magnetic field. 
Methods: Fe3O4 nanoparticles were synthesized and incorporated into spherical CHX 
particles and the powder was freeze dried. Resin disc specimens were produced using a 
UDMA-HEMA resin mixed with freeze dried spherical Fe3O4-CHX particles (5 wt. %), which 
were placed into a Teflon mould (10 mm diameter × 1 mm depth) and covered with a Mylar 
strip. A MACS magnet was left in contact for 0 mins (Group 1), 5 mins (Group 2) or 10 mins 
(Group 3) and the resin discs subsequently light cured (Bluedent LED pen, Bulgaria) for 60 s 
per side. The resin discs were immersed in deionised water at various time points up to 650 h. 
UV-Vis absorbance was used to determine the CHX content. CHX released for each time point 
was determined. The functionalized CHX particles and resin discs were characterized using 
TEM, TGA, EDX and SEM. 
Results: Fe3O4 nanoparticles (20 nm) incorporated into the spherical CHX particles, led to a 
mean (SD) particle size reduction from 17.15 (1.99) µm to 10.39 (2.61) µm. The presence of 
Fe3O4 nanoparticles in the spherical CHX particles was confirmed with SEM, EDX, and TGA. 
SEM of group 1 resin discs (no magnetic exposure) showed functionalized CHX spheres were 
homogeneously distributed within the resin discs. For resin discs which had magnetic exposure 
(5 or 10 mins) the particles started to cluster nearer the surface (Group 2: 43.7%, Group 3: 
57.3%), to a depth of 94 µm. UV-Vis absorbance revealed Group 1 resin discs had a cumulative 
CHX release of 4.4% compared to 5.9 % for group 2 and 7.4% for group 3 resin discs, which 





Antibacterial agents and their delivery are of great importance in medicine and dentistry, since 
a wide range of bacterial infections are still the major reasons for recurrent/ persistent infections 
despite the use of antibiotics [1, 2]. Biomaterial implants used in modern medicine for 
functional restorations are also susceptible to infections, which can lead to failure [3]. Increased 
application of implants in dentistry has led to significant numbers of patients developing peri-
implantitis (47.1% prevalence with mean functional loading of 10 years) [4]. These painful 
infections are caused by anaerobic bacteria and lead to bone loss, exposure of titanium implant 
threads and ultimately implant removal. Painful surgical treatment, smoothing of the implant 
[5] and cleaning together with antibiotic therapy can be carried out, but many of these treatment 
strategies have poor outcomes [6]. The site of bacterial infections can also be largely 
inaccessible to antimicrobial agents used in the oral cavity, especially in periodontal pockets 
and proximal/marginal areas of composite restorations, which are susceptible to bacterial 
micro-leakage. This can lead to the establishment of bacterial biofilms causing secondary caries, 
inflammation and degradation of the polymer composite [7]. Bacteria may become resistant if 
the antibacterial agents cannot penetrate the biofilm and if sufficient drug is not available at 
the infection site [8, 9]. Therefore efficient delivery and penetration of the antibacterial agent 
to the exact site of infection is highly desirable. In some infection, enhanced antimicrobial drug 
delivery might be achieved by using a non-invasive external magnetic force to improve drug 
navigation to the infection site. Magnetic field navigated drug delivery is based on the use of 
magnetic nanoparticles such as  magnetite, strontium ferrite, manganese ferrite and others [10] 
embedded into different nano-/micro- carriers or used directly, and various therapeutic agents 
have been loaded for magnetic targeted delivery [11-14]. Recent studies have demonstrated 
that by using a magnetic field superparamagnetic iron oxide nanoparticles are able to target 
infection sites, inhibit several bacterial functions and penetrate biofilms; thereby overcoming 
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the therapeutic barrier often encountered when using traditional antibiotics or other 
antibacterial agents [3, 9]. In dentistry, magnetic nanoparticles have been incorporated into 
polymeric scaffolds or cement composites to enhance cell adhesion and osteogenic 
differentiation [15-17] and have been navigated inside dental tubules via an external magnetic 
field for treating dental hypersensitivity [18]. Magnetic nanoparticles are also combined with 
other components to enhance their antibacterial performance. Mahmoudi et al., reported core-
shell nanoparticles consisting of a superparamagnetic core and silver shell, which showed 
enhanced antimicrobial activities and excellent penetration of biofilms when an external 
magnetic field was applied [19].  
CHX is a bis-biguanide antiseptic and disinfectant extensively used in medicine and dentistry 
[20, 21]. The current authors previously developed a novel formulation of CHX with a 
controllable crystal size [22] and release behavior when incorporated into a  dental resin [23]. 
Functionalisation of the novel CHX particles with gold nano-rods resulted in the ability to 
produce a near-infrared light (NIR) responsive CHX release [24]. With the ability to move 
CHX to an infection site using an external magnetic field, the combination of magnetic 
nanoparticles with CHX crystals could extend the range of antibacterial applications and 
improve efficacy. Therefore we aim to functionalise the novel CHX particles with iron oxide 
nanoparticles (Fe3O4) and investigate the possibility of moving the resulting CHX composite 
in a dental resin with an external magnetic field. There are many clinical situations where a 
targeted drug release would be desirable in restorative dentistry, periodontology and medicine. 
Magnetic responsive CHX formulations may be particularly useful in developing magnetic 






2. Materials and Methods 
2.1 Magnetic nanoparticles synthesis 
Iron oxide nanoparticles (Fe3O4) were synthesized according to a well-established Massart’s 
co-precipitation method [25]. Briefly, 2.35g FeCl3 (Fluka, 44944, Lot: 30607125) and 0.86g 
FeCl2 (Fluka, 44939, Lot: 24606139) were added in 40 ml H2O in a three-neck flask, and then 
placed in an oil bath and heated up to 80 oC in an argon atmosphere. The mixture was next 
stirred using a magnetic stirrer (VWR Stirrer, USA), at a rate of 800 rpm, whilst 5 ml NH4OH 
(Sigma-Aldrich, UK, lot: 320145) was added slowly with a syringe. Heating was maintained 
at 80 oC for 30 mins and then 2 ml of 0.5g/ml citric acid (Sigma-Aldrich, UK, 27490, Lot: 
23405C03) was introduced. The temperature was next raised to 95 oC and held for 90 mins. 
The product was cooled and dialysed against H2O in a 14 kDa cut-off membrane (Sigma-
Aldrich, UK, D9527) for one week. The Fe3O4 nanoparticles were then characterized using 
transmission electron microscopy (TEM) (JEOL-JEM 2010, USA) at acceleration voltage of 
200 kV. 
2.2 Fe3O4-Chlorhexidine sphere synthesis 
Spherical CHX particles (SCPs) were functionalized with Fe3O4 nanoparticles and prepared 
by mixing 200 µl of Fe3O4 nanoparticle suspension with 1 ml of 0.33M CaCl2 (Sigma-Aldrich, 
UK, C8106, Lot: SLBF7416V). The mixture was added to 1 ml of 15 mg/ml CHX-diacetate 
solution (Sigma-Aldrich, UK, C6143, Lot: 19H0417). The mixtures were shaken for 1 min, 
and then centrifuged at 2000 rpm for 1 min (Eppendorf centrifuge, 5417C, Germany). To 
reduce the dissolution of the particles, the precipitates were washed three times with 0.33M 
CaCl2 solution. All the supernatants were collected for UV-Vis absorbance (Wavelength = 254 
nm). The functionalized CHX spheres (CHX/Fe3O4) were freeze dried (ScanVac Cool Safe 
Freeze Drying, Denmark) at -107 oC, 0.009 mBar for 1 day. The proportion of CHX in the 
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powders was calculated using both UV-Vis (Lambda 35, Perkin Elmer, USA) and thermo-
gravimetric analysis (TGA Q50) as described in our previous work [23]. Control SCPs (without 
Fe3O4 nanoparticles) were synthesized by co-precipitation of CaCl2 and CHX-diacetate, as 
described in our previous study [26]. 
 
2.3 Preparation of functionalized chlorhexidine UDMA- HEMA resin discs 
UDMA-HEMA resin was prepared by mixing 64% urethane dimethacrylate (UDMA) 
(Esschem, UK, Lot: 591-22), 36% hydroxyethyl methacrylate (HEMA) (Aldrich, UK), 0.08% 
of N, N-dimethyl-P-toluidine (Acros Organics, UK) and 0.05% dimethylamino ethyl 
methacrylate (Aldrich, UK). The mixture was stirred at 800 rpm for 15 min (VWR Stirrer, 
USA). Finally, camphorquinone (Sigma-Aldrich, UK) was added at the proportion of 0.1% and 
the mixture was stirred for another 15 min. The viscous liquid resin was next mixed for 1 min 
with the freeze dried CHX/Fe3O4 spheres (5 wt.% CHX content) using a Rotomix (120V/60Hz, 
2850 rotations/min) (ESPE RotoMix, USA).  
The resin mixture containing CHX/Fe3O4 spheres was placed into a Teflon mould (10 mm in 
diameter ×1 mm depth), left for 10 mins and then cured through a Mylar film with a curing 
light (Bluedent LED pen, Bulgaria) (430-490nm, 600 mW/sq.cm) for 60 s on both sides (Group 
1). To control the distribution of CHX/Fe3O4 particles in the resin mixture, it was again placed 
into the Teflon mould and covered with a Mylar film. A MACS magnet (1.5 cm diameter, 0.5 
cm depth, Miltenyi Biotech, UK) was left in contact for 5 mins (Group 2) or 10 mins (Group 
3) and then the resin discs were light cured for 60 s per side. All the discs were next weighed 
on a microbalance (Salter Ander-180A weighing scale, UK) and the amount of CHX in each 




2.4 UV/VIS Spectroscopy  
The release kinetics of CHX from the resin discs was measured using UV-Vis absorption 
(Lambda 35, Perkin Elmer, USA). All the UDMA-HEMA resin discs containing CHX/Fe3O4 
spheres were kept in cuvettes containing 2 ml deionized water at room temperature. Specimen 
Groups 1, 2 and 3 (n=3 per group) were tested at time points of 1h, 3h, 5h, 15h, 25h, 40h, 65h, 
95h, 140h, 205h, 275h, 350h, 500h and 650h. Solutions from each time interval were collected 
for the UV-vis absorbance test and replaced with fresh deionised H2O. The released CHX for 
each time point was determined according to an established calibration curve [23]. Residual 
CHX in all the supernatants was determined by measuring the UV absorption of the 
supernatants at 254 nm. Cumulative release for each of the groups was plotted and compared. 
 
2.5 Scanning electron microscopy (SEM) characterization  
The spherical CHX particles, CHX/Fe3O4 spheres and resin discs containing CHX/Fe3O4 
spheres (Groups 1-3) were characterised using SEM. The resin discs containing CHX/Fe3O4 
spheres were immersed in liquid nitrogen and fractured to analyse the distribution of spheres. 
All the samples were gold coated for 45s at 18 mA, 0.04 mBar using a sputter coater (SC7620, 
Emitech, UK) and viewed using a scanning electron microscope (FEI Inspect-F, USA), in the 
secondary electron imaging mode, with an accelerating voltage of 10 kv and spot size of 3.5. 
To identify the presence of Fe in the CHX/Fe3O4 spheres, energy dispersive X-ray 
spectroscopy (EDX), (INCA, Oxford Instruments, High Wycombe, UK) was used with an 
accelerating voltage of 20 kV, working distance of 10 mm and spot size of 5. Back scattered 
SEM images were also used to illustrate the distribution of Fe in the CHX/Fe3O4 spheres. 
To determine the influence of Fe3O4 nanoparticles on the size of spherical CHX particles, the 
Mean (SD) particle diameter of the spherical CHX particles and functionalized CHX particles 
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(CHX/Fe3O4) were measured using quantitative image analysis software (Nano Measurer, 
version 1.2) of the SEM images.  
Resin discs containing CHX/Fe3O4 spheres with 0 mins (Group 1), 5 mins (Group 2) or 10 
mins (Group 3) magnetic exposure were characterized using SEM using the above protocol. 
To acquire a panoramic image, cross-sectional SEM images were taken continuously from one 
side of the resin disc to the other side and then all the individual images were assembled to 
produce a panoramic image. To analyze the distribution of CHX/Fe3O4 spheres in the resin 
discs as a function of distance to the magnet, the panoramic images for each group (n=3 per 
group) were divided into 21 frames. Each frame was presented along the x-axis in 47 µm 
increments. The number of CHX/Fe3O4 spheres in each of the frames was counted and 
summed to get the total number. The CHX/Fe3O4 sphere distribution in the resin discs was 
plotted as a function of frame distance to the magnet side, with each point representing the 
percentage of CHX particles in each frame accordingly. The border of the frame next to the 
magnet was set as zero.   
In order to assess the influence of magnetism on particle distribution the number of CHX/Fe3O4 
particles in each frame (n=3 in each of the three test groups) were statistically compared using 
a one way ANOVA (p<0.05, Tukey test, Sigma stat, version 2.03, SPSS Inc.).  
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2.6 Cytotoxicity Assay 
The Cytotoxicity of CHX/Fe3O4 spheres were evaluated with a standard MTT (3-[4,5 
dimethylthiazol-2-yl]-2, 5 diphenyl tetrazolium bromide) assay using L929 fibroblast cell line 
(ECACC 85011425, UK). The MTT assay was carried out according to the protocol outlined 
in ISO 10993-5:2009 (Biological evaluation of medical devices - Part 5: Tests for in vitro 
cytotoxicity). Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Lonza, 
UK) supplemented with 10% fetal bovine serum (FBS) with 100 IU/mL penicillin, 100 μg/ml 
streptomycin, and 2 mmol/L glutamine (all from Invitrogen, UK) in a humidified incubator in 
10% CO2 in air at 37°C seeded in flat bottom 96-well microtiter plates (Sarstedt, Germany) at 
104 cells per well with a final volume of 225μl and incubated for 22 hours. Following 
incubation, a series of 2 fold dilutions (0.000625 % to 0.08 %) of CHX/Fe3O4, commercial 
chlorhexidine diacetate (CHX) and pure Fe3O4 nanoparticles in deionised water were prepared. 
25μl of each CHX/Fe3O4, CHX and pure Fe3O4 nanoparticle concentration was added into 
respective 96-well flat-bottomed microtiter plates to achieve a final CHX/Fe3O4, CHX and 
pure Fe3O4 nanoparticle concentration range of 0.0000625 % to 0.008 %. 25μl of sterile 
deionized water were added into the control wells (cells only and medium only) and plates 
were incubated for 24 hours. Culture medium containing the treatments was then removed and 
50 μL of 1 mg/mL tetrazolium salt MTT (Sigma-Aldrich, Gillingham, UK) was added to each 
well and incubated in 37 °C for 2 hours. Formazan crystals generated by mitochondrial enzyme 
activity were then dissolved by 100 µl of isopropanol and the intensity of the purple coloured 
reaction product was quantified by measuring the absorbance spectra with a plate reader at 570 
nm. The absorbance of untreated cells was considered to be 100%. Relative cell viability was 
calculated as: (absorbance of treated cells/absorbance of untreated cells) x 100%. Finally, an 
inverted microscope (Nikon Eclipse TE2000-S, UK) was used to image the morphology of 
treated and untreated cells. 
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2.7 Antimicrobial Assay 
Oral pathogenic bacterium, Porphyromonas gingivalis (strain W50) was used to evaluate the 
antibacterial activity of CHX/Fe3O4. P. gingivalis was grown on blood agar (Blood Agar Base 
No. 2; Oxoid, UK) plates in an anaerobic atmosphere (10% H2, 10% CO2, and 80% N2) at 
37°C for 48 hours. The bacterial culture was harvested and suspended in brain heart infusion 
(BHI) broth (CM1135; Oxoid, UK) supplemented with 5µg/ml haemin and 5µg/ml menadione 
bisulphite. The bacterial culture was then grown for 24 hours anaerobically after which it was 
adjusted to an initial optical density (OD) of 0.1 at 600 nm (OD600nm) with BHI broth. A series 
of 2 fold dilutions (from 0.08 % to 0.000625 %) of CHX/Fe3O4 in deionised water were 
prepared. 225μl of diluted bacteria and 25μl of each CHX/Fe3O4 concentration was mixed into 
96-well flat-bottomed microtiter plates to achieve a final CHX/Fe3O4 concentration range of 
0.008 % to 0.0000625 %. For control wells (bacterial suspension only and BHI only), 25μl of 
sterile deionized water were added. The plates were incubated for 24 hours anaerobically and 
OD was determined at 595 nm (OD595nm) to quantify bacterial growth. The lowest CHX/Fe3O4 
concentration with no detectable bacterial growth was recorded as the minimum inhibitory 
concentration (MIC). Additionally, MTT assay was carried out as described above to determine 
the viability of treated bacteria. Briefly, bacterial culture medium containing different 
CHX/Fe3O4 concentrations were removed, 50 μL of 1 mg/mL tetrazolium salt MTT (Sigma-
Aldrich, Gillingham, UK) was added to each well and incubated anaerobically for 2 hours. 
Formazan crystals were then dissolved with 100 µl of isopropanol and absorbance was 
measured at 570 nm. Bacterial viability was calculated as: absorbance of treated 






3.1 Results of the TEM study 
TEM image of synthesized Fe3O4 nanoparticles is showed in Figure 1. It can be seen that the 
mean diameter (SD) of the nanoparticles is 13.1 (2.4) nm and they appeared in clusters.  
3.2 Results of the SEM study 
SEM photomicrographs of the SCP and CHX/Fe3O4 spheres is shown in Figure 2a, e and 2b, 
f. Spherical CHX particles were produced by co-precipitation of chlorhexidine diacetate and 
CaCl2. Both samples showed a porous structure and particles were monodispersed (Figs. 2a-f). 
The mean (SD) diameter for SCP was 17.15 (1.99) µm, whilst the CHX/Fe3O4 spheres had a 
mean (SD) diameter of 10.39 (2.61) µm. SEM photomicrographs at high magnification 
(×40,000) indicated a dendritic structure for both particles (Figs. 2c-d), but Fe3O4 nanoparticles 
appeared dispersed within the structure for the functionalized particle (Fig. 2d). SEM images 
in the back scattered mode illustrated the presence of Fe in the CHX/Fe3O4 spheres (Fig. 2f), 
which was not present in the SCP (Fig. 2e) and peaks for Fe were clearly identified using EDX 
(Fig. 3). 
The cross-sectional SEM images of resin discs (Groups 1-3) assembled to make panoramic 
images are presented in Figures 5a, b, c. Frames (indicated by white lines, first 3 numbered) 
are presented in 47 µm increments and the position of the magnet (M) is marked to indicate the 
magnet side. For the Group 1 resin discs with no magnetic exposure (Fig. 5a), the CHX/Fe3O4 
spheres were homogeneously distributed throughout the resin discs. The Group 2 and 3 
specimens (5 and 10 mins magnetic exposure) resulted in the clustering of many of the 
CHX/Fe3O4 spheres at the magnet end (Figs. 5b, c). According to the numbers of magnetic 
CHX/Fe3O4 spheres counted in each of the frames, their distribution was plotted as a function 
of distance from the magnet (Figs. 6 a, b, c). To gauge the effects of the magnetic field the 
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percentage of particles in the first three frames (nearest the magnet) and in the disc with no 
treatment are listed. Group 1 frames were; 1: 8.4 %, 2: 3.6 % and 3: 7.1 % (Fig 6a). Group 2 
(5 min magnetic exposure) frames were; 1: 22.9%, 2: 20.8%, 3: 7.1% and Group 3 (10 min 
magnetic exposure) were 1: 38%, 2: 19.3% and 3: 5.5% (Figs 6 b, c). The results of the 
statistical analysis of particles in the SEM frames (1-3) were highly significant (p<0.01) and 
are given in Table 1. The power of the performed test with alpha was 0.050:1.0. 
 
3.3 Results of the Thermo-gravimetric analysis 
The results of the TGA analysis are shown in Figure 4. The spherical CHX particles (SCP) had 
8.5 wt.% remaining after increasing the temperature to 800 oC [24], and for the Fe3O4 
functionalized CHX spheres there was 33 wt.% remaining.  
 
3.4 Release kinetics of CHX from resin 
The release of CHX from the HEMA-UDMA resin discs containing functionalized 
CHX/Fe3O4 spheres (Groups 1-3), demonstrated a two stage process (Fig. 7). In the first stage 
there was a burst release (until 200 h) which was more rapid for Groups 2 and 3 when compared 
to Group 1. The second stage of the plots demonstrated a sustained release for all groups. Group 
1 (no magnetic treatment) resulted in 4.4% CHX released, whilst Group 2 (5 min magnetic 
treatment) gave 5.9% CHX released and Group 3 (10 min magnetic treatment) resulted in 7.4% 







3.5 Cytotoxicity Assay Results 
The results of the cytotoxicity assay are presented in Figure 8a. Treatment with functionalized 
chlorhexidine spheres (CHX/Fe3O4) and commercial chlorhexidine diacetate (CHX) reduced 
cell viability in a dose-dependent manner in vitro. Overall, CHX/Fe3O4 spheres demonstrated 
reduced cytotoxicity in comparison with CHX at the same concentration. 
Relative cellular viability was reduced to approximately 50% in 0.0005% CHX treated cultures 
whilst the viability was above 80% in CHX/Fe3O4 sphere treated cells. While viability 
remained >70% in CHX/Fe3O4 sphere treated cells at 0.001% concentration, CHX treated cells 
demonstrated reduced viability (~30%) (Fig.8a). Accordingly, changes in cellular morphology 
(rounded, swelled, and loss of attachment to the wells) were also observed in both 0.0005% 
and 0.001% CHX treated cultures, whilst the normal morphology was maintained in 
CHX/Fe3O4 sphere treated cultures (Fig. 8b-d).  
3.6 Antimicrobial Assay Results 
Figure 9 shows the antimicrobial activity of CHX/Fe3O4 against P.gingivalis. The growth of 
P. gingivalis was completely inhibited by 0.0005% wt./vol. CHX/Fe3O4 (MIC) (Figure 9a) as 
measured by culture optical density. The MTT assay also confirmed this MIC value with no 






The antibacterial activities of metal nanoparticles such as gold, silver, copper, zinc and titanium 
and their applications against bacterial infections are well established [27]. In the current study 
Fe3O4 nanoparticles with an mean (SD) diameter of 13.1 (2.4) nm (Fig. 1) were synthesized 
using a co-precipitation method to take advantage of their ferrimagnetic properties [28] and 
allow targeted CHX drug release. Magnetic nanoparticles are extensively used for targeted drug 
delivery and as diagnostic agents due to their excellent magnetic properties, superior 
biocompatibility and ease of functionalization [14]. Magnetite (Fe3O4) is an inverse spinel 
structure with various particle morphologies that include spherical, octahedral or cubic 
structures [29]. The cubic structure is known to grow via a screw dislocation process [30]. In 
this study TEM of the precipitated Fe3O4 nanoparticles appeared to show signs of spherical 
morphology, although this was indistinct. The shape, size and surface chemical functionalities 
of iron oxide nanoparticles have a profound effect on their antibacterial activities [3]. When 
tested, CHX/Fe3O4 demonstrated antimicrobial activity against the periodontal pathogen P. 
gingivalis (Fig. 9). Importantly the cytotoxicity assay results showed that the CHX/Fe3O4 
treated cells maintained >90% viability at the concentration that inhibited bacterial growth (Fig. 
8a). Furthermore, Fe3O4 nanoparticle alone treated cells demonstrated >90% viability even in 
the highest treatment concentration tested (0.008%), whilst commercial CHX diacetate treated 
cells were not viable. This demonstrates that Fe3O4 nanoparticles were not cytotoxic to the 
fibroblastic cells (Fig. 8a). Magnetic targeted superparamagnetic iron oxide nanoparticles have 
been shown to be active against Staphylococcus epidermidis biofilms and may be an effective 
alternative to antibiotics for antibiotic-resistant strains [3]. They also appear more effective in 
penetrating and inhibiting biofilms compared with traditional antibiotics [9]. The antibacterial 
mechanisms associated with metal nanoparticles include their electrostatic attraction to the 
negatively charged bacterial cell membrane, their high surface area to volume particle ratio [31] 
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and production of a reactive oxygen species, ensuring intimate membrane contact and leading 
to functional disorder of the bacterial cells [3]. The dynamic series of interfacial interactions 
between nanoparticles and biological structures are however very complex [32].  
The crystallization of the CHX compound onto the Fe3O4 nanoparticles in the present study is 
advantageous as it presents an opportunity for a dual and tailored antibacterial effect. Enhanced 
antibacterial activity might also be obtained through the release of Fe3O4 nanoparticles through 
the dissolution of CHX from the sphere structure. Such a possibility would be valuable in 
treating antibiotic resistant bacterial biofilms but remains to be demonstrated.  
Functionalization of the CHX spheres using the Fe3O4 nanoparticles appeared to dramatically 
decrease the mean (SD) CHX particle diameter from 17.15 (1.99) µm for the particles with no 
functionalization (Figs. 2a, 2e) to 10.39 (2.61) µm for the CHX/Fe3O4 spheres (Figs. 2b, 2f). 
However, the spherical morphology and structure appeared unchanged (Figs. 2c-f). These metal 
ions may also act as sites for CHX crystallization, where the co-precipitation system 
encourages surface crystallization. Previous work indicated that functionalizing the CHX 
spheres with gold nanorods resulted in correlation between the number of nanoparticles added 
and the mean CHX particle diameter and number (r2=0.98) [24]. It is hypothesized that this 
might be possible with a number of metal ions including Fe3O4. The present work was directed 
towards the magnetic properties associated with ferrimagnetic domains in the Fe3O4 structure 
(tetrahedral and octahedral sub-lattices) [29], enabling a magnetic responsive drug release 
behavior. The Fe3O4 nanoparticles identified in this study are known to interact with each other 
and problems have been posed with functionalizing these particles for different applications 
[33]. Domains of the excess Fe3O4 nanoparticles were identified trapped within the CHX 
crystal structure (Figs. 2d, 2f, 3), which enhanced the magnetic effect and allowed the 
CHX/Fe3O4 particle movement. 
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The spherical CHX particles produced by co-precipitation of CaCl2 and chlorhexidine diacetate 
had a very high drug content (> 90 wt.%). After TGA analysis (Fig. 4) the remaining weight 
of the spherical CHX particles was 8.5 wt.%, which was ascribed to the presence of CaCl2 and 
chlorhexidine diacetate/degradation products [23]. When the CHX particles were 
functionalized with Fe3O4 nanoparticles, the remaining weight increased to 33 wt.% (Fig. 4), 
which was due to the non-decomposing metal nanoparticles at high temperature. Therefore 
24.5 wt.% of Fe3O4 nanoparticles were calculated to have been incorporated into the CHX 
particles and this proportionally reduced CHX content may be the reason for the reduced 
cytotoxicity observed against fibroblastic cells in comparison with CHX at the same 
concentration (Fig. 8). 
Magnetic nanoparticles are largely incorporated within carriers together with drugs resulting 
in a low drug loading rate [34]. The current strategy overcomes this problem as it was possible 
to grow the CHX drug (67 wt.%) directly onto the surface of metal nanoparticles and trap them 
within its structure (Figs. 2d, 2f). There are many studies using magnetic nanoparticles for 
targeted delivery, but this is the first study to integrate magnetic nanoparticles directly into 
drug crystals. This method promotes intimate contact between the metal nanoparticles and 
CHX crystals that can improve both plasmonic [24] and magnetic sensitivity, broadening the 
range of drug delivery methods. This also allows the potential of varying the Fe3O4 
nanoparticle content to tailor these properties and to control the size, number and CHX/ Fe3O4 
sphere ratio via particle crystallisation. 
Functionalization of the CHX spheres allowed the particles to be moved in the viscous HEMA-
UDMA resin in response to application of an external magnetic force (Figs. 5b, 5c). The resin 
sample without magnetic exposure presented a homogeneous distribution of CHX/Fe3O4 
spheres across the SEM cross sectional samples (Figs. 5a, 6a), which were evenly distributed 
by the resin mechanical mixing prior to curing. There was also no statistical difference (p>0.05) 
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between the number of spheres present in SEM frames 1-3 indicating this to a depth of 141 
microns. Following magnetic exposure (5 and 10 mins) there was a significant increase (p<0.01) 
in the number of CHX/ Fe3O4 spheres to a depth of 94 microns from the surface (Fig 5b, 5c, 
6b, 6c) nearest to the magnet. This represented 43.7%- 57.3% of the CHX/ Fe3O4 spheres in 
the samples (Figs. 6 b, 6c). At a depth >94 microns (Frames 3, Figs. 5b, 5c) from the surface 
nearest the magnet the CHX/ Fe3O4 sphere number was reduced and not significantly different 
to the CHX/ Fe3O4 sphere distribution (frame 3, group 1) with no magnetic exposure (Table 1, 
P>0.05). Clearly with magnetic exposure there was bulk movement of the CHX/ Fe3O4 spheres 
towards the magnet. The strength of the magnetic field was a key factor, and the magnetic field 
currently used was 400 mT at the magnet surface. Magnetic field strength has been shown to 
drop rapidly as a function of distance from the surface for Fe3O4 nanoparticles incorporated in 
microcapsules (1.3 um diameter) and dispersed in cell suspensions [35]. The current work 
necessitated the movement of the larger mean (SD) 10.39 (2.61) µm diameter CHX/ Fe3O4 
spheres through a viscous HEMA-UDMA resin and with a Mylar film (1 mm depth) used in 
the disc fabrication process, further reducing the magnetic fields influence. This would explain 
the residual CHX/ Fe3O4 spheres remaining in the SEM frames furthest away from the magnet 
(Figs 6 b, 6c). Further work is required on the type of magnet/magnetic field strength and 
duration on the movement of the drug particles to optimise this process. More efficient 
synthesis of cubic nanoparticles could also affect their magnetic sensitivity [36], allowing a 
stronger magnetic field to be used to reduce the exposure time. Guardia et al [37] suggested 
that cube-shaped (polydispersity <20%) Fe3O4 nanoparticles (19 nm) were in the transition 
between superparamagnetic and ferromagnetic particles, which yields high magneto-thermal 
properties. The magnetic attraction of CHX/ Fe3O4 spheres and their directed movement 
through a dental polymer or gel is extremely desirable, as it allows the drug to be moved to the 
infection site to potentially kill the bacteria more efficiently. Antibacterial agents of this kind 
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navigated by an external magnetic field resulted in an 8-fold higher antibacterial effectiveness 
in comparison to using antibiotics [3]. The current CHX/ Fe3O4 spheres might therefore be 
effective in sites in the oral cavity inaccessible to current antimicrobial agents, such as deep 
periodontal pockets or sites susceptible to secondary caries.  
 
The release kinetics of CHX/ Fe3O4 spheres from the HEMA-UDMA resin demonstrated a 
twostage process. Utilising a magnetic field (5 and 10 mins) to draw the CHX/ Fe3O4 spheres 
to the surface appeared to have the effect of inducing a more rapid drug release in the initial 
stages (until 200 h) from 2.9% (no magnetic field) to 4.0% (5 min) or 4.5% (10 min) (Fig. 7). 
Near surface drug entrapment and rapid leaching in water explains this burst effect [38, 39]. 
Inhibition of the polymerisation process by the increased CHX content in the near specimen 
surface (94 µm) and the presence of residual monomers /unreacted hydrophilic components 
encouraging water sorption of the polymer [40, 41]. After a 650 h sustained CHX release the 
overall drug content was also increased from 4.4% to 7.4% (10 min magnetic exposure). Most 
of the CHX incorporated in the Group 1 resin discs remained in the resin due to the 
homogeneous distribution of CHX/ Fe3O4 spheres throughout the sample interior (Group 1, 
Fig 5a), which limited the volume fraction of CHX/ Fe3O4 spheres available for rapid 
dissolution and diffusion mechanisms near the surface [41]. Synthesis of spherical CHX 
particles (without functionalization) by co-precipitation of CaCl2 and chlorhexidine diacetate 
indicated that the particles were stable, less soluble and with lower CHX release rates than the 
chlorhexidine diacetate counterpart when dispersed in resin [23]. This can be attributed to Cl- 
ions in their structure [42] and has been linked to the CHX release kinetics [22]. Following 
application of a magnetic field for 5-10 mins the CHX/ Fe3O4 spheres (43.7%- 57.3%) were 
drawn to a depth of 94 microns from the surface of the polymer (Fig 5b, 5c, 6b, 6c). The 
diffusion of CHX is determined by the water droplets formed around the drug particles, which 
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form pathways or channels linked to the surface [43]. It is therefore not surprising that the resin 
discs with more CHX/ Fe3O4 spheres distributed near the surface had higher release rates. 
Mechanisms for CHX/ Fe3O4 sphere dissolution appeared to be via the central part of the 
particle which was more prevalent for spheres nearer the resin surface than the interior. This 
dissolution behavior was thought to be associated with the penetration and intimate contact 
between the resin and the interior CHX/ Fe3O4 sphere structure [23]. The magnetic CHX/ 
Fe3O4 spheres embedded in resin could therefore also be further triggered with an alternating 
magnetic field to induce a responsive release [33, 44, 45], which will be explored in future 
work. 
The functionalized CHX spheres (CHX/ Fe3O4) have a number of potential applications and 
this is the first study to demonstrate novel magnetic functionalized CHX particles, where their 
distribution in a resin can be manipulated with an external magnetic field to alter the CHX 
release kinetics. These particles could be incorporated into dental filling materials and used to 
restore exposed implant surfaces or dispersed into maxillo-facial/ denture lining materials, 
allowing magnetically directed and drug responsive properties. These magnetic CHX/ Fe3O4 
spheres dispersed in gels and varnishes etc. are particularly attractive for the treatment of 
persistent periodontal or biomaterial-implant-associated infections.  
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Figure 6, Plots of the distribution of Fe3O4 /CHX spheres in HEMA-UDMA resin disc 
as a function of magnetic field treatment. (a) without magnetic field treatment; 
(b) with magnetic field treatment for 5 min; (c) with magnetic field treatment 
for 10 min. 
 
Figure 7, Release kinetics of chlorhexidine from the HEMA-UDMA resin disc as a 
function of magnetic field treatment. black line= without magnetic field 
treatment; red line= with magnetic field treatment for 5 min; blue line= with 
magnetic treatment for 10 min. 
 
Figure 8, (a) Relative viability of fibroblast cells following treatment with Fe3O4 
nanoparticles, CHX and CHX/Fe3O4 spheres (results averaged from three 
independent experiments).  Light microscopy images of cell morphology in; 
(b) untreated-0%; (c) CHX/Fe3O4 (0.001%) and; (d) Chlorhexidine diacetate 
(0.001%).  
Figure 9  (a) Growth of P. gingivalis was determined by measuring OD 595nm at 0 h 
after 24 h. (b) Relative viability of P. gingivalis following 24 h treatment with 
CHX/Fe3O4 (results averaged from three independent experiments and shown 
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*Significant differences are indicated by different superscript letters between groups (P<0.05). 
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